Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5545965 in negative symptoms of schizophrenia
NCT02824055Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO5545965 in schizophrenia (6 arms), sponsored by Roche. Primary endpoints: Apparent volume of distribution, Activity of the ventral striatum during reward expectation in a monetary incentive delay fMRI task and 3 more. Started Jun 2016; status: completed.
02
Drugs
RO5545965
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02824055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824055.